Gossamer Bio, Inc.

GOSSSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1728117

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$0.00	—	—	—	—
Operating Expenses	$218.6M	$216.1M	$234.0M	$186.1M	$149.0M
Operating Income (Loss)	-$218.6M	-$216.1M	-$234.0M	-$186.1M	-$149.0M
Interest Expense	—	$19.4M	$12.7M	$1.9M	$12.0K
Nonoperating Income (Expense)	-$10.8M	-$17.9M	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$229.4M	-$234.0M	-$243.4M	-$180.3M	—
Income Tax Expense (Benefit)	$0.00	—	—	—	—
Net Income (Loss) Attributable to Parent	-$229.4M	-$234.0M	-$243.4M	-$180.3M	-$147.0M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$311.9M	$272.4M	$343.7M	$539.4M	$426.6M
Assets, Current	$306.5M	$261.9M	$331.8M	$522.3M	$409.3M
Cash and Cash Equivalents, at Carrying Value	$32.1M	$112.0M	$183.4M	$486.1M	$135.0M
Accounts Receivable, after Allowance for Credit Loss, Current	$0.00	—	—	—	—
Liabilities	$249.1M	$260.4M	$222.2M	$218.7M	$74.1M
Liabilities, Current	$51.6M	$49.2M	$39.9M	$38.6M	$36.9M
Long-term Debt	—	—	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$187.0M	-$188.9M	-$176.4M	-$144.8M	-$51.0M
Net Cash Provided by (Used in) Investing Activities	-$1.0M	-$117.4M	$215.3M	-$147.1M	-$144.7M
Net Cash Provided by (Used in) Financing Activities	$117.1M	$3.3M	$312.5M	$321.6M	$300.9M
Payments to Acquire Property, Plant, and Equipment	$410.0K	$1.5M	$1.5M	$3.0M	$3.5M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)